Skip to content
DataLookout
Menu

NCT07908888

Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study

StatusRecruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

2-year progression-free survival (PFS) rate
Timeframe: 2 years

Arms and interventions

Pola-R-miniCHPExperimental

Participants receive polatuzumab vedotin and rituximab combined with reduced-dose cyclophosphamide, doxorubicin and prednisone (Pola-R-miniCHP) for 6 cycles, followed by 2 cycles of rituximab consolidation. Each cycle is 21 days.

Drugs: Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone

Sites

1 site in 1 country

  • The First Hospital of Jilin UniversityChangchun, Jilin, China